



IFW 1644  
PTO/SB/21 (08-03)

## TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

		Application Number	09/707,738
		Filing Date	November 6, 2000
		First Named Inventor	Sette, Alessandro
		Art Unit	1644
		Examiner Name	Vander Vegt, Francois Pierre
Total Number of Pages in This Submission		Attorney Docket Number	018623-006250US

### ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) <i>(please identify below):</i> Return Postcard Copy of Notice to Comply Sequence listing on paper Sequence listing on disk	
		<input type="checkbox"/> Remarks	
		The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.	


### SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual	Townsend and Townsend and Crew LLP Matthew E. Hinsch	Reg. No. 47,651
Signature		
Date	January 6, 2004	

### CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Joy M. Marshall		
Signature		Date	January 6, 2004



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Mail Stop: Sequence  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

On January 6, 2004

TOWNSEND and TOWNSEND and CREW LLP

By: joy m. marshal

PATENT  
Attorney Docket No.: 018623-006250US  
Client Ref. No.: EPI 0062.50  
Customer No.: 20350

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

SETTE *et al.*

Application No.: 09/707,738

Filed: November 6, 2000

## For: INDUCTION OF IMMUNE RESPONSE AGAINST DESIRED DETERMINANTS

Confirmation No. 8820

Examiner: Vander Vegt, Francois Pierre

Art Unit: 1644

## COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

## AMENDMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, that accompanied the Office Communication mailed December 15, 2003, Applicants submit herewith the required paper copy and computer readable copy of the Substitute Sequence Listing. Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows.

Appl. No. 09/707,738  
Amtd. dated January 6, 2004  
Reply to Notice to Comply of December 15, 2003

PATENT

**Amendments to the Specification** begin on page 3 of this paper.

**Remarks** begin on page 4 of this paper.